Clinical Trial Site Monitoring Visit Checklist [FREE PDF]
Clinical research associates (CRAs) use this checklist for site monitoring visits per FDA 21 CFR 312 IND requirements and ICH GCP E6(R2) good clinical practice guidelines.
- Industry: Pharmaceutical / Clinical Research
- Frequency: Per Visit
- Estimated Time: 25-30 minutes
- Role: Clinical Research Associate
- Total Items: 8
- Compliance: FDA 21 CFR 312, ICH GCP E6(R2)
Source Data Verification & CRFs
Verify source data against case report forms.
- Has source data verification been completed for required data points per the plan?
- Have outstanding data queries been reviewed and resolved with site staff?
- Are all active subject informed consents signed with the current IRB-approved version?
- Source verification notes
Investigational Product & Regulatory
Verify IP accountability and regulatory file completeness.
- Is IP accountability log current with dispensing matching subject records?
- Is IP stored per protocol requirements with temperature logs reviewed?
- Is the Investigator Site File (ISF/regulatory binder) complete and up to date?
- IP and regulatory notes
Related Clinical Operations Checklists
- Surgical Site Infection (SSI) Prevention Bundle Checklist [FREE PDF]
- Central Line Insertion (CLABSI Prevention) Checklist [FREE PDF]
- Patient Fall Prevention Program Checklist [FREE PDF]
- Radiology Department Safety Program Checklist [FREE PDF]
Why Use This Clinical Trial Site Monitoring Visit Checklist [FREE PDF]?
This clinical trial site monitoring visit checklist [free pdf] helps pharmaceutical / clinical research teams maintain compliance and operational excellence. Designed for clinical research associate professionals, this checklist covers 8 critical inspection points across 2 sections. Recommended frequency: per visit.
Ensures compliance with FDA 21 CFR 312, ICH GCP E6(R2). Regulatory-aligned for audit readiness and inspection documentation.
Frequently Asked Questions
What should a clinical trial monitoring checklist include?
A clinical trial monitoring checklist should cover source data verification (SDV) confirming case report forms match original source documents, protocol deviation review, informed consent documentation verification, investigational product accountability reconciliation, adverse event and serious adverse event reporting timeliness, IRB/IEC approval currency, site staff training records, laboratory certification status, and regulatory binder completeness. Each section should document findings against FDA 21 CFR Part 312 and ICH E6(R2) GCP requirements. The monitor should record corrective actions for any deviation and confirm resolution from the previous visit report.
How often should a clinical trial monitoring checklist be completed?
Monitoring frequency is risk-based and specified in the trial's Monitoring Plan per ICH E6(R2) Section 5.18.3. Active, high-enrollment sites typically require visits every 4–8 weeks. Initiation visits occur before first patient enrollment; close-out visits occur after last patient's last visit. FDA 21 CFR 312.50 requires sponsors to monitor investigations to ensure proper conduct. Unscheduled visits are triggered by protocol deviations, safety signals, or data quality issues. Remote monitoring may supplement on-site visits but cannot fully replace source data verification.
What regulations govern clinical trial monitoring?
Clinical trial monitoring is primarily governed by FDA 21 CFR Part 312 (IND regulations), which establishes sponsor responsibilities for overseeing investigations. ICH E6(R2) Good Clinical Practice, adopted by FDA in 2018, provides the global standard for monitoring practices. FDA 21 CFR Part 50 (informed consent) and Part 56 (IRBs) also apply. EU trials are subject to EU CTR No. 536/2014. Non-compliance can result in FDA Warning Letters, clinical holds, and rejection of trial data in marketing applications, effectively blocking drug approval.
Who is qualified to conduct a clinical trial monitoring inspection?
Clinical Research Associates (CRAs) conducting monitoring visits must have training in GCP, the specific protocol, and the sponsor's monitoring SOPs per ICH E6(R2) Section 5.18.2. Sponsors must document each monitor's education, training, and experience. The Association of Clinical Research Professionals (ACRP) CCRA credential and Society of Clinical Research Associates (SoCRA) CCRP are widely recognized qualifications. FDA inspections of clinical sites are conducted by agency-credentialed Bioresearch Monitoring (BIMO) investigators with specialized clinical research auditing training.
What are the consequences of failing a clinical trial monitoring inspection?
Deficiencies identified during monitoring can result in site-level corrective action plans, increased monitoring frequency, and in severe cases, suspension of enrollment at the site. FDA 483 observations during BIMO inspections, if unresolved, become Warning Letters which can lead to clinical holds under 21 CFR 312.42, halting the trial. Data integrity failures can result in rejection of trial data from the NDA/BLA submission. Willful falsification of clinical data is a federal crime under 18 U.S.C. § 1001 with criminal penalties including imprisonment.
What is a Clinical Trial Site Monitoring Visit Checklist [FREE PDF]?
A Clinical Trial Site Monitoring Visit Checklist [FREE PDF] is a standardized inspection form used by clinical research associate to ensure consistent pharmaceutical / clinical research operations. It contains 11 inspection points organized into 2 sections. FREE clinical trial site monitoring visit checklist. FDA 21 CFR 312 & ICH GCP E6 compliant. 8+ points. Download FREE.
How often should I use this pharmaceutical / clinical research checklist?
This checklist is designed to be completed per visit. Regular use ensures compliance with FDA 21 CFR 312 and ICH GCP E6(R2) and helps identify issues before they become problems.
Can I download this Clinical Trial Site Monitoring Visit Checklist [FREE PDF] as a PDF?
Yes, you can download this checklist as a FREE PDF for printing or offline use. The checklist includes 11 fields across 2 sections and typically takes 25-30 minutes to complete.
What compliance standards does this checklist cover?
This checklist helps ensure compliance with FDA 21 CFR 312, ICH GCP E6(R2). Following these standards protects your organization and ensures best practices.
How do I complete this pharmaceutical / clinical research inspection checklist?
Begin by completing the header fields for Facility Name, Date, and Inspector Name. Work through each of the 2 sections, marking items Yes or No as applicable. Add notes for any issues found. The entire process takes approximately 25 to 30 minutes.
What are the key sections in this pharmaceutical / clinical research checklist?
This pharmaceutical / clinical research checklist is organized into 2 key sections: Source Data Verification & CRFs, Investigational Product & Regulatory. Each section contains specific inspection points that clinical research associate must verify. The structured layout ensures nothing is missed during pharmaceutical / clinical research inspections and makes the process efficient, typically taking 25-30 minutes to complete.
Who should use this Clinical Trial Site Monitoring Visit Checklist [FREE PDF]?
This checklist is primarily designed for clinical research associate working in pharmaceutical / clinical research operations. However, it is also valuable for quality assurance teams, safety officers, compliance managers, and supervisors who need to verify that pharmaceutical / clinical research standards are being met. Organizations of all sizes can benefit from using this Clinical Trial Site Monitoring Visit Checklist [FREE PDF] to maintain consistency and accountability.